<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="1185399f-47c1-4e12-bee5-20198212af65"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use LIVTENCITY safely and effectively. See full prescribing information for LIVTENCITY.<br/>
      <br/> LIVTENCITY<sup>Â®</sup>  (maribavir) tablets, for oral use<br/> Initial U.S. Approval: 2021</title>
   <effectiveTime value="20250304"/>
   <setId root="c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="039997266" root="1.3.6.1.4.1.519.1"/>
            <name>Takeda Pharmaceuticals America, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="962674474" root="1.3.6.1.4.1.519.1"/>
                        <name>Catalent CTS, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="481385565" root="1.3.6.1.4.1.519.1"/>
                        <name>CARBOGEN AMCIS AG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="480055421" root="1.3.6.1.4.1.519.1"/>
                        <name>CARBOGEN AMCIS AG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="480029695" root="1.3.6.1.4.1.519.1"/>
                        <name>CARBOGEN AMCIS AG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="481885861" root="1.3.6.1.4.1.519.1"/>
                        <name>JETPHARMA SA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84386" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PARTICLE SIZE REDUCTION"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="480739627" root="1.3.6.1.4.1.519.1"/>
                        <name>Solvias AG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="332632009" root="1.3.6.1.4.1.519.1"/>
                        <name>Privates Untersuchungsinstitut Heppeler GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="988980314" root="1.3.6.1.4.1.519.1"/>
                        <name>Takeda Ireland Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="985822621" root="1.3.6.1.4.1.519.1"/>
                        <name>Almac Sciences (Ireland) Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="dacc8b6a-f591-4cb6-9d0d-c1e6a4e3aa2b"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240328"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64764-800" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Livtencity</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>MARIBAVIR</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PTB4X93HE1" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MARIBAVIR</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="PTB4X93HE1" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MARIBAVIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Microcrystalline cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C Blue NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="28" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="64764-800-28" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20211123"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="56" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="64764-800-56" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20211123"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215596" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20211123"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">SHP;620</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="06acdf98-190b-468f-a88a-c9aeccc3cd56"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20240328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>LIVTENCITY is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. (<linkHtml href="#S1">1</linkHtml>, <linkHtml href="#S8.4">8.4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="26006ed1-06fa-4202-9c1b-e5217455d0ab"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>400 mg (two 200 mg tablets) orally twice daily with or without food. (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S8.4">8.4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="23b2eeb4-4c05-4d1e-bfff-ecd6dc3b4465"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage </title>
                     <text>
                        <paragraph>The recommended dosage in adults and pediatric patients (12 years of age and older and weighing at least 35 kg) is 400 mg (two 200 mg tablets) taken orally twice daily with or without food <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="569ad10b-8bd3-4f71-90e0-61d314541c45"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage Adjustment When Coadministered with Anticonvulsants</title>
                     <text>
                        <paragraph>If LIVTENCITY is coadministered with carbamazepine, increase the dosage of LIVTENCITY to 800 mg (four 200 mg tablets) twice daily <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>. 								</paragraph>
                        <paragraph>If LIVTENCITY is coadministered with phenytoin or phenobarbital, increase the dosage of LIVTENCITY to 1,200 mg (six 200 mg tablets) twice daily <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="d4c50d8b-46ec-4640-8aaf-81de5350c706"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Administration</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">The immediate-release tablets can be taken as whole, dispersed or crushed tablets by mouth, or as dispersed tablets through a nasogastric or orogastric tube (French size 10 or larger). The suspension may be prepared ahead of time and stored at room temperature for up to 8 hours.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="8edbda03-8ff6-4123-8008-c8b4cbbd8aac"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Administration of Dispersed Tablets or Crushed Tablets by Mouth</content>
                                 </content>
                              </paragraph>
                              <list listType="ordered" styleCode="Arabic">
                                 <item>
                                    <content styleCode="xmChange">Place the appropriate number of tablets for the prescribed dose into a suitable container. If desired, the tablets may be crushed. Add the appropriate volume of drinking water (other liquids have not been tested) to make a suspension <content styleCode="italics">(see <linkHtml href="#table1">Table 1</linkHtml> below)</content>.</content>
                                    <table width="90%" ID="table1">
                                       <caption>Table 1: Number of Tablets and Volume of Drinking Water Needed to Make a Suspension for Administration of Dispersed or Crushed Tablets by Mouth</caption>
                                       <col width="33%" align="center" valign="middle"/>
                                       <col width="33%" align="center" valign="middle"/>
                                       <col width="34%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">
                                                <content styleCode="xmChange">Recommended Dosage</content>
                                             </th>
                                             <th styleCode="Rrule">Number of 200 mg Tablets </th>
                                             <th styleCode="Rrule">Volume of Drinking Water</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="xmChange">400 mg</content>
                                             </td>
                                             <td styleCode="Rrule">Two</td>
                                             <td styleCode="Rrule">30 mL</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="xmChange">800 mg</content>
                                             </td>
                                             <td styleCode="Rrule">Four</td>
                                             <td styleCode="Rrule">60 mL</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="xmChange">1,200 mg</content>
                                             </td>
                                             <td styleCode="Rrule">Six</td>
                                             <td styleCode="Rrule">90 mL</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange"> Swirl the container gently to keep the particles from settling, and administer the suspension before it settles. The mixture will have a bitter taste.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Rinse the container with 15 mL of drinking water and administer the rinse water.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Repeat Step 3. Visually confirm that no particles are left in the container. If particles remain, repeat Step 3.</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="efa21688-0f52-4f0c-8722-822f74ec526d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Administration of Dispersed Tablets through a Nasogastric (NG) or Orogastric (OG) Tube</content>
                                 </content>
                              </paragraph>
                              <list listType="ordered" styleCode="Arabic">
                                 <item>
                                    <content styleCode="xmChange">Remove the cap (if applicable) and plunger out of a 50 or 60 mL catheter-tip compatible syringe or equivalent. Add two tablets into the syringe body and place the plunger back in the syringe. Only two tablets can be administered via NG or OG tube at a time.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Draw 30 mL of drinking water (other liquids have not been tested) into the syringe and hold the syringe with the tip pointing upward. Pull the plunger further to a higher volume position to have some air space in the syringe. Place the cap back on the syringe (if applicable). Shake the syringe well (careful not to spill the contents) for about 30 to 45 seconds or until the tablets are completely dispersed.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Once the tablets are completely dispersed in the syringe, remove the cap from the syringe again (if applicable) and attach the syringe to the NG or OG tube and administer the dispersion before it settles.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Draw 15 mL of water using the same syringe and flush through the same NG or OG tube.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Repeat Step 4 and make sure no particles are left in the syringe by visual inspection. If particles remain, repeat Step 4.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">For doses of 800 mg (four 200 mg tablets) and 1,200 mg (six 200 mg tablets) <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>, repeat Steps 1-5 until prescribed dose is reached. The same syringe, NG or OG tube can be used.</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="d5e311e9-335e-4a2a-ad56-125803d279fe"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablet: 200 mg, blue, oval shaped convex tablet debossed with "SHP" on one side and "620" on the other side.</paragraph>
               </text>
               <effectiveTime value="20240328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 200 mg of maribavir. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="6696151a-a6cc-4109-8686-803c981c1875"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20240328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="685f1702-ce7d-4154-b84f-390db993bf61"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list styleCode="disc" listType="unordered">
                           <item>LIVTENCITY may antagonize the antiviral activity of ganciclovir and valganciclovir. Coadministration is not recommended. (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Virologic failure can occur during and after treatment with LIVTENCITY. Monitor CMV DNA levels and check for resistance if patient does not respond to treatment. Some maribavir pUL97 resistance-associated substitutions confer cross-resistance to ganciclovir and valganciclovir.  (<linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S12.4">12.4</linkHtml>, <linkHtml href="#S14.1">14.1</linkHtml>)</item>
                           <item>The concomitant use of LIVTENCITY and certain drugs may result in potentially significant drug interactions, some of which may lead to reduced therapeutic effect of LIVTENCITY or adverse reactions of concomitant drugs. (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>, <linkHtml href="#S7.2">7.2</linkHtml>, <linkHtml href="#S7.3">7.3</linkHtml>)</item>
                           <item>LIVTENCITY has the potential to increase the drug concentrations of immunosuppressant drugs that are CYP3A4 and/or P-gp substrates where minimal concentration changes may lead to serious adverse events (including tacrolimus, cyclosporine, sirolimus and everolimus). Frequently monitor immunosuppressant drug levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust the dose, as needed. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="bec9d133-195f-4762-bc25-456102117a0c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risk of Reduced Antiviral Activity When Coadministered with Ganciclovir and Valganciclovir</title>
                     <text>
                        <paragraph>LIVTENCITY may antagonize the antiviral activity of ganciclovir and valganciclovir by inhibiting human CMV pUL97 kinase, which is required for activation/phosphorylation of ganciclovir and valganciclovir. Coadministration of LIVTENCITY with ganciclovir or valganciclovir is not recommended <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml> and <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="4a6ff4dd-af2a-46d4-acab-5f020df1ee6a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Virologic Failure During Treatment and Relapse Post-Treatment</title>
                     <text>
                        <paragraph>Virologic failure due to resistance can occur during and after treatment with LIVTENCITY. Virologic relapse during the post-treatment period usually occurred within 4-8 weeks after treatment discontinuation. Some maribavir pUL97 resistance-associated substitutions confer cross-resistance to ganciclovir and valganciclovir. Monitor CMV DNA levels and check for maribavir resistance if the patient is not responding to treatment or relapses <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml> and <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="b8399cc0-e307-4890-84ff-e98c2cb635ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions</title>
                     <text>
                        <paragraph>The concomitant use of LIVTENCITY and certain drugs may result in potentially significant drug interactions, some of which may lead to reduced therapeutic effect of LIVTENCITY or adverse reactions of concomitant drugs <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                        <paragraph>See <linkHtml href="#Table4">Table 4</linkHtml> for steps to prevent or manage these possible or known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during LIVTENCITY therapy; review concomitant medications during LIVTENCITY therapy and monitor for adverse reactions.</paragraph>
                        <paragraph>Maribavir is primarily metabolized by CYP3A4. Drugs that are strong inducers of CYP3A4 are expected to decrease maribavir plasma concentrations and may result in reduced virologic response; therefore, coadministration of LIVTENCITY with these drugs is not recommended, except for selected anticonvulsants <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="8c56d569-a473-424d-a22a-152caa4136aa"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Use with Immunosuppressant Drugs</content>
                              </paragraph>
                              <paragraph>LIVTENCITY has the potential to increase the drug concentrations of immunosuppressant drugs that are CYP3A4 and/or P-glycoprotein (P-gp) substrates where minimal concentration changes may lead to serious adverse events (including tacrolimus, cyclosporine, sirolimus and everolimus). Frequently monitor immunosuppressant drug levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust the immunosuppressant dose, as needed <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. 										</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="eab38398-5057-4192-ae2d-2cfb78b79e59"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20240328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse events (all grades, &gt;10%) in subjects treated with LIVTENCITY were taste disturbance, nausea, diarrhea, vomiting, and fatigue. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="1b7e8887-27b8-4b02-9b69-dcdf465551b2"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of LIVTENCITY was evaluated in one Phase 3 multicenter, randomized, open-label, active-control trial in which 352 adult transplant recipients were randomized, and treated with LIVTENCITY (N=234) or Investigator-Assigned Treatment (IAT) consisting of monotherapy or dual therapy with ganciclovir, valganciclovir, foscarnet, or cidofovir as dosed by the investigator (N=116) for up to 8-weeks following a diagnosis of CMV infection/disease refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, foscarnet or cidofovir. The mean treatment durations (SD) for LIVTENCITY and IAT were 48.6 (Â± 13.82) and 31.2 (Â± 16.91) days, respectively. The most common adverse events occurring in more than 10% of subjects receiving LIVTENCITY are outlined in Table 2.</paragraph>
                        <table width="75%">
                           <caption>Table 2: Adverse Events (All Grades) Reported in &gt;10% of Subjects in the LIVTENCITY Group in Trial 303</caption>
                           <col width="32%" align="left" valign="top"/>
                           <col width="36%" align="center" valign="top"/>
                           <col width="32%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th valign="middle" align="center" styleCode="Lrule Rrule">ADVERSE EVENT</th>
                                 <th styleCode="Rrule">LIVTENCITY<br/> N=234<br/> (%)</th>
                                 <th styleCode="Rrule">IAT<footnote>IAT (Investigator-Assigned Treatment) included monotherapy or dual therapy with ganciclovir, valganciclovir, foscarnet, or cidofovir as dosed by the investigator.</footnote>
                                    <br/> N=116<br/> (%)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Taste disturbance<footnote>taste disturbance includes the following reported preferred terms: ageusia, dysgeusia, hypogeusia and taste disorder.</footnote>
                                 </td>
                                 <td styleCode="Rrule">46</td>
                                 <td styleCode="Rrule">4</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Nausea</td>
                                 <td styleCode="Rrule">21</td>
                                 <td styleCode="Rrule">22</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Diarrhea</td>
                                 <td styleCode="Rrule">19</td>
                                 <td styleCode="Rrule">21</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Vomiting</td>
                                 <td styleCode="Rrule">14</td>
                                 <td styleCode="Rrule">16</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Fatigue</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">9</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Similar proportions of subjects experienced serious adverse events (38% in the LIVTENCITY group and 37% in the IAT group). The most common serious adverse event in both treatment groups occurred in the Infections and Infestations System Organ Class (SOC) (23% in the LIVTENCITY group and 15% in the IAT group) with CMV infection and disease being the most common in both groups.</paragraph>
                        <paragraph>A higher proportion of subjects in the IAT group discontinued study medication due to an adverse event compared to the LIVTENCITY group (32% in the IAT group vs 13% in the LIVTENCITY group). The most commonly reported causes that led to study drug discontinuation were neutropenia (9%) and acute kidney injury (5%) in the IAT group and dysgeusia, diarrhea, nausea, and recurrence of underlying disease (each reported at 1%) in the LIVTENCITY group.</paragraph>
                        <paragraph>Taste disturbance occurred in 46% of subjects treated with LIVTENCITY. These events rarely led to discontinuation of LIVTENCITY (1%) and, for 37% of the subjects, these events resolved while on therapy (median duration 43 days; range 7 to 59 days). For the subjects with ongoing taste disturbance after drug discontinuation, resolution occurred in 89%. In subjects with resolution of symptoms after drug discontinuation, the median duration of symptoms off treatment was 6 days (range 2 to 85 days).</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="ed9d2b2d-4071-455c-907f-f57e640e4aeb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Laboratory Abnormalities</content>
                              </paragraph>
                              <paragraph>Selected laboratory abnormalities reported in subjects with refractory (with or without genotypic resistance) CMV infections in Trial 303 are presented in Table 3.</paragraph>
                              <table width="75%">
                                 <caption>Table 3: Selected Laboratory Abnormalities Reported in Trial 303</caption>
                                 <col width="34%" align="left" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th valign="middle" align="center" styleCode="Lrule Rrule">Laboratory Parameter</th>
                                       <th styleCode="Rrule">LIVTENCITY<br/> N=234<br/>  n (%)</th>
                                       <th styleCode="Rrule">IAT<br/> N=116<br/>  n (%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Neutrophils (cells/ÂµL)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â &lt;500</td>
                                       <td styleCode="Rrule">4 (2)</td>
                                       <td styleCode="Rrule">4 (3)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â â¥500 to &lt;750</td>
                                       <td styleCode="Rrule">7 (3)</td>
                                       <td styleCode="Rrule">7 (6)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â â¥750 to &lt;1,000</td>
                                       <td styleCode="Rrule">10 (4)</td>
                                       <td styleCode="Rrule">6 (5)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Hemoglobin (g/dL)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â &lt;6.5</td>
                                       <td styleCode="Rrule">3 (1)</td>
                                       <td styleCode="Rrule">1 (1)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â â¥6.5 to &lt;8.0</td>
                                       <td styleCode="Rrule">34 (15)</td>
                                       <td styleCode="Rrule">23 (20)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â â¥8.0 to &lt;9.5</td>
                                       <td styleCode="Rrule">76 (32)</td>
                                       <td styleCode="Rrule">33 (28)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Platelets (cells/ÂµL)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â &lt;25,000</td>
                                       <td styleCode="Rrule">11 (5)</td>
                                       <td styleCode="Rrule">6 (5)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â â¥25,000 to &lt;50,000</td>
                                       <td styleCode="Rrule">27 (12)</td>
                                       <td styleCode="Rrule">10 (9)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â â¥50,000 to &lt;100,000</td>
                                       <td styleCode="Rrule">41 (18)</td>
                                       <td styleCode="Rrule">20 (17)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Creatinine (mg/dL)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â &gt;2.5</td>
                                       <td styleCode="Rrule">16 (7)</td>
                                       <td styleCode="Rrule">12 (10)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â &gt;1.5 to â¤2.5</td>
                                       <td styleCode="Rrule">78 (33)</td>
                                       <td styleCode="Rrule">29 (25)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="a0308298-f398-4011-a915-aea09dfda36d"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list styleCode="disc" listType="unordered">
                           <item>Refer to the full prescribing information for important drug interactions with LIVTENCITY. (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S7">7</linkHtml>)</item>
                           <item>Coadministration with strong CYP3A4 inducers: not recommended. Refer to full prescribing information for dosage modification when coadministered with certain anticonvulsants. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S7.3">7.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="39298539-32f4-46c7-83a1-0f9ea821ecb9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Reduced Antiviral Activity When Coadministered with Ganciclovir or Valganciclovir</title>
                     <text>
                        <paragraph>LIVTENCITY is not recommended to be coadministered with valganciclovir/ganciclovir (vGCV/GCV). LIVTENCITY may antagonize the antiviral activity of ganciclovir and valganciclovir by inhibiting human CMV pUL97 kinase, which is required for activation/phosphorylation of ganciclovir and valganciclovir <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="387aa969-be58-4cc3-bfd9-cf89359e63be"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Potential for Other Drugs to Affect LIVTENCITY</title>
                     <text>
                        <paragraph>Maribavir is a substrate of CYP3A4. Coadministration of LIVTENCITY with strong inducers of CYP3A4 is not recommended, except for selected anticonvulsants <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="81ae4320-4a8a-4086-b3c0-163c0d286c29"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Potential for LIVTENCITY to Affect Other Drugs</title>
                     <text>
                        <paragraph>Maribavir is a weak inhibitor of CYP3A4, and an inhibitor of P-gp and breast cancer resistance protein (BCRP). Coadministration of LIVTENCITY with drugs that are sensitive substrates of CYP3A, P-gp and BCRP may result in a clinically relevant increase in plasma concentrations of these substrates <content styleCode="italics">(see <linkHtml href="#Table4">Table 4</linkHtml>)</content>. Table 4 provides a list of established or potentially clinically significant drug interactions, based on either clinical drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or decrease in efficacy <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <table width="85%" ID="Table4">
                           <caption>Table 4: Established and Other Potentially Significant Drug Interactions<footnote>This table is not all inclusive.</footnote>
                           </caption>
                           <col width="30%" align="left" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="50%" align="left" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Concomitant Drug Class: Drug Name</th>
                                 <th styleCode="Rrule" align="left">Effect on Concentration</th>
                                 <th styleCode="Rrule">Clinical Comments</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3">â=decrease, â=increase.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antiarrhythmics</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Digoxin<footnote ID="foot1">The interaction between LIVTENCITY and the concomitant drug was evaluated in a clinical study <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</footnote>
                                 </td>
                                 <td styleCode="Rrule">â Digoxin</td>
                                 <td styleCode="Rrule">Use caution when LIVTENCITY and digoxin are coadministered. Monitor serum digoxin concentrations. The dose of digoxin may need to be reduced when coadministered with LIVTENCITY.<footnote ID="foot2">Refer to the respective prescribing information.</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anticonvulsants</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Carbamazepine</td>
                                 <td styleCode="Rrule">â Maribavir</td>
                                 <td styleCode="Rrule">A dose adjustment of LIVTENCITY to 800 mg twice daily is recommended when coadministered with carbamazepine.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Phenobarbital</td>
                                 <td styleCode="Rrule">â Maribavir</td>
                                 <td styleCode="Rrule">A dose adjustment of LIVTENCITY to 1,200 mg twice daily is recommended when coadministration with phenobarbital.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Phenytoin</td>
                                 <td styleCode="Rrule">â Maribavir</td>
                                 <td styleCode="Rrule">A dose adjustment of LIVTENCITY to 1,200 mg twice daily is recommended when coadministration with phenytoin.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antimycobacterials</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Â Â Rifabutin</td>
                                 <td styleCode="Rrule" valign="middle">â Maribavir</td>
                                 <td styleCode="Rrule">Coadministration of LIVTENCITY and rifabutin is not recommended due to potential for a decrease in efficacy of LIVTENCITY.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Rifampin<footnoteRef IDREF="foot1"/>
                                 </td>
                                 <td styleCode="Rrule">â Maribavir</td>
                                 <td styleCode="Rrule">Coadministration of LIVTENCITY and rifampin is not recommended due to potential for a decrease in efficacy of LIVTENCITY.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Herbal Products</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â St. John's wort</td>
                                 <td styleCode="Rrule">â Maribavir</td>
                                 <td styleCode="Rrule">Coadministration of LIVTENCITY and St. John's wort is not recommended due to potential for a decrease in efficacy of LIVTENCITY. </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">HMG-CoA Reductase Inhibitors</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Rosuvastatin<footnoteRef IDREF="foot2"/>
                                 </td>
                                 <td styleCode="Rrule">â Rosuvastatin</td>
                                 <td styleCode="Rrule">The patient should be closely monitored for rosuvastatin-related events, especially the occurrence of myopathy and rhabdomyolysis.<footnoteRef IDREF="foot2"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Immunosuppressants</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Cyclosporine</td>
                                 <td styleCode="Rrule">â Cyclosporine</td>
                                 <td styleCode="Rrule">Frequently monitor cyclosporine levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed.<footnoteRef IDREF="foot2"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Everolimus</td>
                                 <td styleCode="Rrule">â Everolimus</td>
                                 <td styleCode="Rrule">Frequently monitor everolimus levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed.<footnoteRef IDREF="foot2"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Sirolimus</td>
                                 <td styleCode="Rrule">â Sirolimus</td>
                                 <td styleCode="Rrule">Frequently monitor sirolimus levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed.<footnoteRef IDREF="foot2"/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Tacrolimus<footnoteRef IDREF="foot1"/>
                                 </td>
                                 <td styleCode="Rrule">â Tacrolimus</td>
                                 <td styleCode="Rrule">Frequently monitor tacrolimus levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed.<footnoteRef IDREF="foot2"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="6e20f202-37f6-4348-9987-ce1e62f847b5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Drugs without Clinically Significant Interactions with LIVTENCITY</title>
                     <text>
                        <paragraph>No clinically significant interactions were observed in clinical drug-drug interaction studies of LIVTENCITY and ketoconazole, antacid, caffeine, warfarin, voriconazole, dextromethorphan, or midazolam <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="61b6beb8-9aa8-47e6-b290-44f1dfdb8c61"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240328"/>
               <component>
                  <section ID="S8.1">
                     <id root="5cf417fa-2a39-46e6-a14b-adad6939fa6d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="2fc82c80-3121-4ecc-802c-2dd47166c4ac"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>No adequate human data are available to establish whether LIVTENCITY poses a risk to pregnancy outcomes. In animal reproduction studies, embryo-fetal survival was decreased in rats, but not in rabbits, at maribavir exposures less than those observed in humans at the recommended human dose (RHD) <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="2a8d825e-fb0e-442d-872f-da82c27dffd5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                           <component>
                              <section>
                                 <id root="3d1e5025-bba8-4ca1-84ac-1a2fe65dc4cb"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In a combined fertility and embryofetal development study, maribavir was administered to male and female rats at oral doses of 100, 200, or 400 mg/kg/day. Females were dosed for 15 consecutive days prior to pairing, throughout pairing, and up to gestation day (GD) 17, while males were dosed 29 days prior to mating and throughout mating. A decrease in the number of viable fetuses and increase in early resorptions and post-implantation losses were observed at â¥100 mg/kg/day (at exposures approximately half the human exposure at the RHD). Intermittent reduced body weight gain was observed in pregnant animals at â¥200 mg/kg/day. Maribavir had no effect on embryo-fetal growth or development at dose levels up to 400 mg/kg/day, at exposures similar to those observed in humans at the RHD.</paragraph>
                                    <paragraph>No significant toxicological effects on embryo-fetal growth or development were observed in rabbits when maribavir was administered at oral doses up to 100 mg/kg/day from GD 8 to 20, at exposures approximately half the human exposure at the RHD.</paragraph>
                                    <paragraph>In the pre-and post-natal developmental toxicity study, maribavir was administered to pregnant rats at oral doses of 50, 150, or 400 mg/kg/day from GD 7 to post-natal day (PND) 21. A delay in developmental milestones was observed, including pinna detachment at doses â¥150 mg/kg/day and eye opening and preputial separation associated with reduced bodyweight gain of the offspring at 400 mg/kg/day. In addition, decreased fetal survival and litter loss was observed due to maternal toxicity and poor maternal care, respectively, at doses â¥150 mg/kg/day. No effects were observed at 50 mg/kg/day (which is estimated to be less than the human exposure at the RHD). No effects on number of offspring, proportion of males, number of live pups, or survival to PND 4 were observed at any dose in the offspring born to the second generation.</paragraph>
                                 </text>
                                 <effectiveTime value="20240328"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="fbd446c5-7d34-4b13-b421-8ae845a7ceb1"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="fc5a392f-6c1c-4dc6-970e-621127268e82"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>It is not known whether maribavir or its metabolites are present in human or animal milk, affect milk production, or have effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for LIVTENCITY and any potential adverse effects to the breast-fed child.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="ef4110eb-9d30-4d73-a87f-c2d2b68bb6f1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The recommended dosing regimen in pediatric patients 12 years of age and older and weighing at least 35 kg is the same as that in adults. Use of LIVTENCITY in this age group is based on the following:</paragraph>
                        <list styleCode="disc" listType="unordered">
                           <item>Evidence from controlled studies of LIVTENCITY in adults</item>
                           <item>Population pharmacokinetic (PK) modeling and simulation demonstrating that age and body weight had no clinically meaningful effect on plasma exposures of LIVTENCITY</item>
                           <item>LIVTENCITY exposure is expected to be similar between adults and children 12 years of age and older and weighing at least 35 kg</item>
                           <item>The course of the disease is similar between adults and pediatric patients to allow extrapolation of data in adults to pediatric patients <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>
                           </item>
                        </list>
                        <paragraph>The safety and effectiveness of LIVTENCITY have not been established in children younger than 12 years of age.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="42a21e28-9bc5-4c74-b187-9ad7bc985753"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No dosage adjustment is required for patients over 65 years of age based on the results from population pharmacokinetics analysis <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content> and efficacy and safety data from the clinical studies. In the clinical Study 303, 54 patients aged 65 years and over were treated with LIVTENCITY. Safety, effectiveness, and pharmacokinetics were consistent between elderly patients (â¥65 years) and younger patients (&lt;65 years).</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="9b0e7428-d9a6-4375-ab3e-fe9d71cd50ba"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6	Impaired Renal Function</title>
                     <text>
                        <paragraph>No dose adjustment of LIVTENCITY is needed for patients with mild, moderate, or severe renal impairment <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Administration of LIVTENCITY in patients with end stage renal disease (ESRD), including patients on dialysis, has not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="05a4acf0-b82c-4276-bcfc-150c812cd9c8"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7	Impaired Hepatic Function</title>
                     <text>
                        <paragraph>No dose adjustment of LIVTENCITY is needed for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Administration of LIVTENCITY in patients with severe hepatic impairment has not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="5d430a67-e50d-440a-a600-a99b5b78a052"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>There is no known specific antidote for LIVTENCITY. In case of overdose, it is recommended that the patient be monitored for adverse reactions and appropriate symptomatic treatment instituted. Due to the high plasma protein binding of LIVTENCITY, dialysis is unlikely to reduce plasma concentrations of LIVTENCITY significantly.</paragraph>
               </text>
               <effectiveTime value="20240328"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="e86e1b1e-87e3-4192-97d2-5d105555ec0e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>LIVTENCITY tablets contain maribavir, a benzimidazole riboside CMV pUL97 protein kinase inhibitor. The chemical name of maribavir is 5,6-Dichloro-<content styleCode="italics">N</content>-(1-methylethyl)-1-Î²-L-ribofuranosyl-1<content styleCode="italics">H</content>-benzimidazol-2-amine and the structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>The molecular formula for maribavir is C<sub>15</sub>H<sub>19</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>4</sub> and its molecular weight is 376.23.</paragraph>
                  <paragraph>Each 200 mg tablet for oral administration contains 200 mg maribavir and the following inactive ingredients: FD&amp;C Blue #1, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium starch glycolate, titanium dioxide, and talc.</paragraph>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="livtencity-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="dec5c876-c31a-42e0-81fc-ab20335f2769"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240328"/>
               <component>
                  <section ID="S12.1">
                     <id root="cfb0fe12-557c-42cf-b2c9-7f543f83e873"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>LIVTENCITY is an antiviral drug against human CMV <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="6d16291d-287b-4c67-a046-347b09bbbd53"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="220ab3ae-c79e-4a50-aaf0-279d6c0d12fd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Exposure-Response</content>
                              </paragraph>
                              <paragraph>In dose-ranging studies that evaluated doses of 400 mg twice daily and twice daily doses of two and three times the recommended dose, no exposure-response relationship was observed for viral load or probability of unquantifiable plasma CMV DNA.</paragraph>
                              <paragraph>In Phase 3 Trial 303 that evaluated a maribavir dose of 400 mg twice daily, increasing maribavir exposure was not associated with increased probability of confirmed plasma CMV DNA &lt; LLOQ (lower limit of quantification) at Week 8.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="fcab9804-cd8d-4a63-85ca-85c8ccaaf3d3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>At three times the recommended dose (approximately twice the peak concentration observed following the recommended dose), LIVTENCITY does not prolong the QT interval to any clinically relevant extent.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="5c90a924-be78-4dac-8016-6a2b3afc342c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>LIVTENCITY pharmacological activity is due to the parent drug. Following oral administration, plasma maribavir exposure (C<sub>max</sub> and AUC) increased approximately dose-proportionally following a single dose of 50 to 1600 mg (0.125 to four times the recommended dose) and multiple doses up to 2400 mg per day (three times the recommended daily dose). Maribavir PK is time-independent. With twice-daily dosing, steady state is reached within 2 days, with mean accumulation ratios of C<sub>max</sub> and AUC ranging from 1.37 to 1.47.</paragraph>
                        <paragraph>The pharmacokinetic properties of maribavir following administration of LIVTENCITY are displayed in Table 5. The multiple-dose pharmacokinetic parameters are provided in Table 6.</paragraph>
                        <table width="90%">
                           <caption>Table 5: Pharmacokinetic Properties of Maribavir</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">Absorption<footnote>When taken orally with a high fat, high caloric meal vs fasted, the AUC<sub>0ââ</sub> and C<sub>max</sub> (geometric mean ratio [90% CI] of maribavir are 0.878 [0.843, 0.915] and 0.716 [0.671, 0.764], respectively.</footnote>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">T<sub>max</sub> (h), median</td>
                                 <td styleCode="Rrule">1.0 to 3.0</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">Distribution</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Mean apparent steady-state volume of distribution (V<sub>ss</sub>, L)</td>
                                 <td styleCode="Rrule">24.9</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">% bound to human plasma proteins </td>
                                 <td styleCode="Rrule">98.0 across the concentration range of 0.05-200 Âµg/mL</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Blood-to plasma ratio</td>
                                 <td styleCode="Rrule">1.37</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">Elimination </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Major route of elimination</td>
                                 <td styleCode="Rrule">Hepatic metabolism</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Half-life (t<sub>1/2</sub>) in transplant patients (h), mean</td>
                                 <td styleCode="Rrule">4.32</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Oral clearance (CL/F) in transplant patients (L/h), mean</td>
                                 <td styleCode="Rrule">2.67</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="italics">Metabolism</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Metabolic pathways<footnote>
                                       <content styleCode="italics">In vitro</content> studies have shown that maribavir is biotransformed into a major circulating inactive metabolite: VP 44469 (N-dealkylated metabolite), with a metabolic ratio of 0.15 - 0.20. Multiple UGT enzymes, namely UGT1A1, UGT1A3, UGT2B7, and possibly UGT1A9, are involved in the glucuronidation of maribavir in humans, however, the contribution of glucuronidation to the overall clearance of maribavir is low based on <content styleCode="italics">In vitro</content> data.</footnote>
                                 </td>
                                 <td styleCode="Rrule">CYP3A4 (major) and CYP1A2 (minor)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Excretion</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">% of dose excreted as total <sup>14</sup>C (unchanged drug) in urine<footnote ID="foot4">Dosing in mass balance study: single-dose administration of [<sup>14</sup>C] maribavir oral solution 400 mg containing 200 nCi of total radioactivity.</footnote>
                                 </td>
                                 <td styleCode="Rrule">61 (&lt;2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">% of dose excreted as total <sup>14</sup>C (unchanged drug) in feces<footnoteRef IDREF="foot4"/>
                                 </td>
                                 <td styleCode="Rrule">14 (5.7)</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="90%">
                           <caption>Table 6: Multiple-Dose Pharmacokinetic Parameters of Maribavir</caption>
                           <col width="32%" align="center" valign="top"/>
                           <col width="34%" align="center" valign="top"/>
                           <col width="34%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule" colspan="3">	Geometric Mean (% CV)<footnote>Pharmacokinetic parameter values based on post-hoc estimates from maribavir population pharmacokinetic model in transplant patients with CMV receiving 400 mg of LIVTENCITY twice daily with or without food.</footnote>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule">AUC<sub>0-tau</sub>
                                    <footnote>tau is maribavir dosing interval: 12 hours.</footnote>
                                    <br/> (Âµgâh/mL)</th>
                                 <th styleCode="Rrule">C<sub>max</sub>
                                    <br/> (Âµg/mL)</th>
                                 <th styleCode="Rrule">C<sub>tau</sub>
                                    <br/>	(Âµg/mL)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left">CV=Coefficient of Variation; C<sub>max</sub>=Maximum concentration; AUC<sub>0-tau</sub>=Area under the time concentration curve over a dosing interval; C<sub>tau</sub>=Concentration at the end of a dosing interval.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule">142 (48.5%)</td>
                                 <td styleCode="Rrule">20.1 (35.5%)</td>
                                 <td styleCode="Rrule">5.43 (85.9%)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="d1f6b0f5-9011-452d-ad73-e23f439eab2b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>There were no clinically significant differences in the pharmacokinetics of maribavir based on age (18-79 years), gender, race (Caucasian, Black, Asian, or others), ethnicity (Hispanic/Latino or non-Hispanic/Latino), body weight (36 to 141 kg), transplant type, mild to severe renal impairment (measured creatinine clearance ranging from 12 to 70 mL/min), or mild to moderate hepatic impairment (Child-Pugh Class A or B).</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                           <component>
                              <section>
                                 <id root="832e29f2-e75d-4c33-8279-72a511b8a6f4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of maribavir in patients less than 18 years of age have not been evaluated.</paragraph>
                                    <paragraph>Using modeling and simulation, the recommended dosing regimen is expected to result in comparable steady-state plasma exposures of maribavir in patients 12 years of age and older and weighing at least 35 kg as observed in adults <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]</content>. 												</paragraph>
                                 </text>
                                 <effectiveTime value="20240328"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="14578234-43f8-4121-919f-9f9c9f9962bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions</content>
                              </paragraph>
                              <paragraph>Based on <content styleCode="italics">in vitro</content> studies, the metabolism of maribavir is not mediated by CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A5, UGT1A4, UGT1A6, UGT1A10, or UGT2B15. The transport of maribavir is not mediated by organic anion transporting polypeptide (OATP)1B1, OATP1B3, or bile salt export pump (BSEP).</paragraph>
                              <paragraph>At clinically relevant concentrations, clinically significant interactions are not expected when LIVTENCITY is coadministered with substrates of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP2D6, CYP3A4; uridine diphosphate-glucuronosyltransferase (UGT)1A1, UGT1A4, UGT1A6, UGT1A9, UGT2B7; P-gp; BSEP; multidrug and toxin extrusion protein (MATE)1/2K; organic anion transporters (OAT)1 and OAT3; organic cation transporters (OCT)1 and OCT2; OATP1B1 and OATP1B3. In a clinical drug-drug interaction cocktail study, coadministration with maribavir had no effect on substrates of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.</paragraph>
                              <paragraph>Drug interaction studies were performed with LIVTENCITY and other drugs likely to be coadministered for pharmacokinetic interactions. The effects of coadministration of other drugs on the pharmacokinetics of maribavir are summarized in Table 7, and the effects of maribavir on the pharmacokinetics of coadministered drugs are summarized in Table 8.</paragraph>
                              <paragraph>Dosing recommendations as a result of established and other potentially significant drug-drug interactions with LIVTENCITY are provided in Table 4 <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>.</paragraph>
                              <table width="90%">
                                 <caption>Table 7: Changes in Pharmacokinetics of LIVTENCITY in the Presence of Coadministered Drugs</caption>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="6%" align="center" valign="top"/>
                                 <col width="13%" align="center" valign="top"/>
                                 <col width="13%" align="center" valign="top"/>
                                 <col width="13%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th valign="middle" styleCode="Lrule Rrule" colspan="2" rowspan="2">Coadministered Drug and Regimen</th>
                                       <th valign="middle" styleCode="Rrule" rowspan="2">LIVTENCITY Regimen</th>
                                       <th valign="middle" styleCode="Rrule" rowspan="2">N</th>
                                       <th styleCode="Rrule Botrule" colspan="3">Geometric Mean Ratio (90% CI) of LIVTENCITY PK with/without Coadministered Drug<br/> [No Effect=1.00]</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">AUC</th>
                                       <th styleCode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th styleCode="Rrule">C<sub>tau</sub>
                                          <footnote>tau is maribavir dosing interval: 12 hours.</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="7" align="left">
                                          <content styleCode="bold">Anticonvulsants</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Carbamazepine<footnote ID="foot5">Based on physiologically based pharmacokinetic modeling results from 10 trials of 20 subjects each. The maribavir dosing regimen and geometric mean ratios (5<sup>th</sup> percentile, 95<sup>th</sup> percentile) correspond to dose-adjusted maribavir with inducer vs 400 mg twice daily without inducer.</footnote>
                                       </td>
                                       <td styleCode="Rrule">400 mg once daily</td>
                                       <td styleCode="Rrule">800 mg twice daily / 400 mg twice daily</td>
                                       <td styleCode="Rrule">200</td>
                                       <td styleCode="Rrule">1.40<br/> (1.09, 1.67)</td>
                                       <td styleCode="Rrule">1.53<br/> (1.22, 1.79)</td>
                                       <td styleCode="Rrule">1.05<br/> (0.71, 1.40)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Phenobarbital<footnoteRef IDREF="foot5"/>
                                       </td>
                                       <td styleCode="Rrule">100 mg once daily</td>
                                       <td styleCode="Rrule">1,200 mg twice daily / 400 mg twice daily</td>
                                       <td styleCode="Rrule">200</td>
                                       <td styleCode="Rrule" valign="middle">1.80<br/> (1.18, 2.35)</td>
                                       <td styleCode="Rrule" valign="middle">2.17<br/> (1.69, 2.57)</td>
                                       <td styleCode="Rrule" valign="middle">0.94<br/> (0.22, 1.97)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Phenytoin<footnoteRef IDREF="foot5"/>
                                       </td>
                                       <td styleCode="Rrule">300 mg once daily</td>
                                       <td styleCode="Rrule">1,200 mg twice daily / 400 mg twice daily</td>
                                       <td styleCode="Rrule">200</td>
                                       <td styleCode="Rrule">1.70<br/> (1.06, 2.46)</td>
                                       <td styleCode="Rrule">2.05<br/> (1.49, 2.63)</td>
                                       <td styleCode="Rrule">0.89<br/> (0.26, 2.04)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="7" align="left">
                                          <content styleCode="bold">Antimycobacterials</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rifampin</td>
                                       <td styleCode="Rrule">600 mg once daily</td>
                                       <td styleCode="Rrule">400 mg twice daily</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">0.40<br/> (0.36, 0.44)</td>
                                       <td styleCode="Rrule">0.61<br/> (0.52, 0.72)</td>
                                       <td styleCode="Rrule">0.18<br/> (0.14, 0.25)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="7" align="left">
                                          <content styleCode="bold">Antifungals</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Ketoconazole</td>
                                       <td styleCode="Rrule">400 mg single dose</td>
                                       <td styleCode="Rrule">400 mg single dose</td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">1.53<br/> (1.44, 1.63)</td>
                                       <td styleCode="Rrule">1.10<br/> (1.01, 1.19)</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="7" align="left">
                                          <content styleCode="bold">Antacids</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Aluminum hydroxide and magnesium hydroxide antacid</td>
                                       <td styleCode="Rrule">20 mL<footnote>Containing 800 mg aluminum hydroxide and 800 mg magnesium hydroxide.</footnote> single dose</td>
                                       <td styleCode="Rrule">100 mg single dose</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">0.89<br/> (0.83, 0.96)</td>
                                       <td styleCode="Rrule">0.84<br/> (0.75, 0.94)</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="90%">
                                 <caption>Table 8: Drug Interactions: Changes in Pharmacokinetics for Coadministered Drug in the Presence of 400 mg Twice Daily LIVTENCITY</caption>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="39%" align="center" valign="top"/>
                                 <col width="5%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th valign="middle" styleCode="Lrule Rrule" colspan="2" rowspan="2">Coadministered Drug and Regimen</th>
                                       <th valign="middle" styleCode="Rrule" rowspan="2">N</th>
                                       <th styleCode="Rrule Botrule" colspan="3">Geometric Mean Ratio (90% CI) of Coadministered Drug PK with/without LIVTENCITY<br/> [No Effect=1.00]</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule">AUC</th>
                                       <th styleCode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th styleCode="Rrule">C<sub>tau</sub>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="6" align="left">
                                          <content styleCode="bold">Immunosuppressants</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Tacrolimus</td>
                                       <td styleCode="Rrule">stable dose, twice daily (total daily dose: 0.5-16 mg)</td>
                                       <td styleCode="Rrule">20</td>
                                       <td styleCode="Rrule">1.51<br/> (1.39, 1.65)</td>
                                       <td styleCode="Rrule">1.38<br/> (1.20, 1.57)</td>
                                       <td styleCode="Rrule">1.57<br/> (1.41, 1.74)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="6" align="left">
                                          <content styleCode="bold">P-gp substrate</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Digoxin</td>
                                       <td styleCode="Rrule">0.5 mg<br/> single dose</td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">1.21<br/> (1.10, 1.32)</td>
                                       <td styleCode="Rrule">1.25<br/> (1.13, 1.38)</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="1dc7fe29-be54-4df6-b610-f18fcdbdfe6b"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="2cb638b0-fdb0-44b6-8168-b2c41fba86e1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>The antiviral activity of maribavir is mediated by competitive inhibition of the protein kinase activity of human CMV enzyme pUL97, which results in inhibition of the phosphorylation of proteins. Maribavir inhibited wild-type pUL97 protein kinase in a biochemical assay with an IC<sub>50</sub> value of 0.003 ÂµM. Maribavir and its 5'-mono- and 5'-triphosphate derivatives at 100 ÂµM had no significant effect on the incorporation of deoxynucleoside triphosphates by human CMV DNA polymerase. At a concentration of 100 ÂµM, neither maribavir nor its 5â²-triphosphate derivative inhibited CMV DNA polymerase delta, however the 5â²-monophosphate derivative inhibited incorporation by polymerase delta of all 4 natural dNTPs by approximately 55%.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c7250170-8c70-426e-a52b-d1f381a63d56"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antiviral Activity</content>
                              </paragraph>
                              <paragraph>Maribavir inhibited human CMV replication in virus yield reduction, DNA hybridization, and plaque reduction assays in human lung fibroblast cell line (MRC-5), human embryonic kidney (HEK), and human foreskin fibroblast (MRHF) cells. The EC<sub>50</sub> values ranged from 0.03 to 2.2 ÂµM depending on the cell line and assay endpoint. The cell culture antiviral activity of maribavir has also been evaluated against CMV clinical isolates. The median EC<sub>50</sub> values were 0.1 ÂµM (n=10, range 0.03-0.13 ÂµM) and 0.28 ÂµM (n=10, range 0.12-0.56 ÂµM) using DNA hybridization and plaque reduction assays, respectively. No significant difference in EC<sub>50</sub> values across the four human CMV glycoprotein B genotypes (N=2, 1, 4, and 1 for gB1, gB2, gB3, and gB4, respectively) was seen.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3fd9f038-241a-4821-b4f2-e82ed6dd3a53"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Combination Antiviral Activity</content>
                              </paragraph>
                              <paragraph>When maribavir was tested in combination with other antiviral compounds, antagonism of the antiviral activity was seen in combination with ganciclovir. No antagonism was observed with cidofovir, foscarnet, letermovir and rapamycin at the drugs EC<sub>50</sub> values. The pUL97 kinase activity inhibited by maribavir is necessary to activate valganciclovir/ganciclovir.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1fc39010-1c09-4c45-bb8b-6610f19e83c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Treatment Effect in CMV Glycoprotein B (gB) Subtypes</content>
                              </paragraph>
                              <paragraph>In Trial 303, the primary endpoint response rates for LIVTENCITY across CMV gB subtypes 1, 2, 3, 4, and 5 were 65% (55/85), 39% (22/57), 54% (22/41), 67% (14/21), and 64% (7/11), respectively. The primary endpoint response rates for IAT across CMV gB subtypes 1, 2, 3, 4, and 5 were 28% (15/53), 27% (4/15), 11% (2/19), 20% (2/10), and 17% (1/6), respectively <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="dac7809e-0886-47d6-ab43-3264de5abee3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Viral Resistance</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                           <component>
                              <section>
                                 <id root="caf514f1-3a86-4f76-88ed-55efd40df0e5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Cell Culture</content>
                                    </paragraph>
                                    <paragraph>Selection of maribavir resistant virus in cell culture and genotypic plus phenotypic characterization of these has identified amino acid substitutions that confer reduced susceptibility to maribavir. Substitutions identified in pUL97 include L337M, V353A, L397R, T409M, and H411L/N/Y. These substitutions confer reductions in susceptibility that range from 3.5-fold to &gt;200-fold. Substitutions were also identified in pUL27:R233S, W362R, W153R, L193F, A269T, V353E, L426F, E22stop, W362stop, 218delC, and 301-311del. These substitutions confer reductions in susceptibility that range from 1.7- to 4.8-fold.</paragraph>
                                 </text>
                                 <effectiveTime value="20240328"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="bc2f9279-ae2c-4647-abbf-4462af9128a6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Clinical Studies</content>
                                    </paragraph>
                                    <paragraph>In Phase 2 Study 202 evaluating maribavir in 120 hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) recipients with phenotypic resistance to valganciclovir/ganciclovir, DNA sequence analysis of a select region of pUL97 (amino acids 270 to 482) and pUL27 (amino acids 108 to 424) was performed on 34 paired virologic failure samples. There were 25 patients with treatment-emergent maribavir resistance-associated substitution(s) in pUL97 F342Y (4.5-fold reduction in susceptibility), T409M (78-fold reduction), H411L/Y (69- and 12-fold reduction) and/or C480F (224-fold reduction).</paragraph>
                                    <paragraph>In Phase 3 Study 303 evaluating maribavir in patients with phenotypic resistance to valganciclovir/ganciclovir, DNA sequence analysis of the entire coding regions of pUL97 and pUL27 was performed on 134 paired sequences from maribavir-treated patients. The treatment-emergent pUL97 substitutions F342Y (4.5-fold), T409M (78-fold), H411L/N/Y (69-, 9-, and 12-fold, respectively), and/or C480F (224-fold) were detected in 58 subjects (47 subjects were on-treatment failures and 11 subjects were relapsers). One subject with the pUL27 L193F substitution (2.6-fold reduced susceptibility to maribavir) at baseline did not meet the primary endpoint.</paragraph>
                                 </text>
                                 <effectiveTime value="20240328"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c4bfeeb0-8782-41f6-ae1f-58d986f87262"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cross-Resistance</content>
                              </paragraph>
                              <paragraph>Cross-resistance has been observed between maribavir and ganciclovir/valganciclovir in cell culture and in clinical studies.</paragraph>
                              <paragraph>pUL97 valganciclovir/ganciclovir resistance-associated substitutions F342S/Y, K355del, V356G, D456N, V466G, C480R, P521L, and Y617del reduce susceptibility to maribavir &gt;4.5-fold. Other vGCV/GCV resistance pathways have not been evaluated for cross-resistance to maribavir. pUL54 DNA polymerase substitutions conferring resistance to vGCV/GCV, cidofovir, or foscarnet remained susceptible to maribavir.</paragraph>
                              <paragraph>Substitutions pUL97 F342Y and C480F are maribavir treatment-emergent resistance-associated substitutions that confer &gt;1.5-fold reduced susceptibility to vGCV/GCV, a fold reduction that is associated with phenotypic resistance to vGCV/GCV. The clinical significance of this cross-resistance to vGCV/GCV for these substitutions has not been determined. Maribavir resistant virus remained susceptible to cidofovir and foscarnet. Additionally, there are no reports of any pUL27 maribavir resistance-associated substitutions being evaluated for vGCV/GCV, cidofovir, or foscarnet cross-resistance. Given the lack of resistance-associated substitutions for these drugs mapping to pUL27, cross-resistance is not expected for pUL27 maribavir substitutions.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="09f12a3e-35f3-4b6b-ab74-b14b01cb5987"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240328"/>
               <component>
                  <section ID="S13.1">
                     <id root="2fc54f63-e353-4d00-bef2-08b2434ab23c"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Two-year carcinogenicity studies were conducted in mice and rats administered oral doses up to 150 and 100 mg/kg/day, respectively. Maribavir was not carcinogenic in rats at any dose tested, corresponding to maribavir exposures less than human exposure at the RHD. At 150 mg/kg/day in male mice only, an increased incidence of hemangioma, hemangiosarcoma, and combined hemangioma/hemangiosarcoma was observed across multiple tissues, at exposures less than the human exposure at the RHD. There were no carcinogenic findings in male mice at â¤75 mg/kg/day and female mice at any dose.</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="8d86f7e3-e40f-43f0-ac44-dc48c10a0534"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenicity</content>
                              </paragraph>
                              <paragraph>Maribavir was negative in a bacterial mutation assay and the <content styleCode="italics">in vivo</content> rat bone marrow micronucleus assay. Maribavir was positive in the absence of metabolic activation in the mouse lymphoma assay, and the results were equivocal in the presence of metabolic activation.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="efe24ba3-54c0-4746-8e31-bda2e341918b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Although decreased sperm straight line velocity was observed in males (at maribavir exposures less than those observed in humans at the RHD), there were no effects on fertility in males or females in a combined oral fertility and embryo-fetal study in rats administered maribavir at up to 400 mg/kg/day <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="52980609-efe5-4185-93f7-bc09c386519c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20240328"/>
               <component>
                  <section ID="S14.1">
                     <id root="e79e626d-b2e8-4f1d-b1c1-db4e8a60f205"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Treatment of Adults with Post-Transplant CMV Infection/Disease That Is Refractory (with or without Genotypic Resistance) to Ganciclovir, Valganciclovir, Cidofovir, or Foscarnet  </title>
                     <text>
                        <paragraph>LIVTENCITY was evaluated in a Phase 3, multicenter, randomized, open-label, active-controlled superiority trial (NCT02931539, Trial 303) to assess the efficacy and safety of LIVTENCITY compared to Investigator-Assigned Treatment (IAT) (ganciclovir, valganciclovir, foscarnet, or cidofovir) in 352 HSCT or SOT recipients with CMV infections that were refractory to treatment with ganciclovir, valganciclovir, foscarnet, or cidofovir, including CMV infections with or without confirmed resistance to 1 or more of the IATs. Subjects with CMV disease involving the central nervous system, including the retina, were excluded from the study.</paragraph>
                        <paragraph>Subjects were stratified by transplant type (HSCT or SOT) and screening CMV DNA levels and then randomized in a 2:1 allocation ratio to receive either LIVTENCITY 400 mg twice daily or IAT as dosed by the investigator for up to 8 weeks. After completion of the treatment period, subjects entered a 12-week follow-up phase.</paragraph>
                        <paragraph>The mean age of trial subjects was 53 years and most subjects were male (61%), white (76%) and not Hispanic or Latino (83%), with similar distributions across the two treatment arms. The most common treatment used in the IAT arm was foscarnet which was administered in 47 (41%) subjects followed by ganciclovir or valganciclovir, each administered in 28 (24%) subjects. Cidofovir was administered in 6 subjects, the combination of foscarnet and valganciclovir in 4 subjects and the combination of foscarnet and ganciclovir in 3 subjects. Baseline disease characteristics are summarized in Table 9 below.</paragraph>
                        <table width="85%">
                           <caption>Table 9: Summary of Baseline Disease Characteristics in Trial 303</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th valign="middle" align="center" styleCode="Lrule Rrule" rowspan="2">Characteristic</th>
                                 <th valign="bottom" styleCode="Rrule" align="center">LIVTENCITY<br/> 400 mg Twice Daily<br/>N=235<br/> n (%)</th>
                                 <th valign="bottom" styleCode="Rrule">IAT<br/>N=117<br/> n (%)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left">CMV=cytomegalovirus, DNA=deoxyribonucleic acid, HSCT=hematopoietic stem cell transplant, IAT=investigator assigned anti-CMV treatment, N=number of patients, SOT=solid organ transplant.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Transplant type</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â HSCT</td>
                                 <td styleCode="Rrule">93 (40)</td>
                                 <td styleCode="Rrule">48 (41)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â SOT</td>
                                 <td styleCode="Rrule">142 (60)</td>
                                 <td styleCode="Rrule">69 (59)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Â Â Kidney</td>
                                 <td styleCode="Rrule">74 (52)</td>
                                 <td styleCode="Rrule">32 (46)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Â Â Lung</td>
                                 <td styleCode="Rrule">40 (28)</td>
                                 <td styleCode="Rrule">22 (32)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Â Â Heart</td>
                                 <td styleCode="Rrule">14 (10)</td>
                                 <td styleCode="Rrule">9 (13)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Â Â Other (multiple, liver, pancreas, intestine)</td>
                                 <td styleCode="Rrule">14 (10)</td>
                                 <td styleCode="Rrule">6 (9)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">CMV DNA levels</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Low (&lt;9,100 IU/mL)</td>
                                 <td styleCode="Rrule">153 (65)</td>
                                 <td styleCode="Rrule">85 (73)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Intermediate (â¥9,100 to &lt;91,000 IU/mL)</td>
                                 <td styleCode="Rrule">68 (29)</td>
                                 <td styleCode="Rrule">25 (21)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â High (â¥91,000 IU/mL)</td>
                                 <td styleCode="Rrule">14 (6)</td>
                                 <td styleCode="Rrule">7 (6)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Confirmed symptomatic CMV infection at baseline</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â No</td>
                                 <td styleCode="Rrule">214 (91)</td>
                                 <td styleCode="Rrule">109 (93)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Yes<footnote ID="foot6">one of the subjects had both CMV syndrome and disease but was counted for CMV disease only.</footnote>
                                 </td>
                                 <td styleCode="Rrule">21 (9)</td>
                                 <td styleCode="Rrule">8 (7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Â Â CMV syndrome (SOT only)</td>
                                 <td styleCode="Rrule">9 (43)</td>
                                 <td styleCode="Rrule">7 (88)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Â Â Tissue Invasive disease</td>
                                 <td styleCode="Rrule">12 (57)<footnoteRef IDREF="foot6"/>
                                 </td>
                                 <td styleCode="Rrule">1 (13)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240328"/>
                     <component>
                        <section>
                           <id root="0986508a-1e9e-45b6-b9a7-a58a668ce34e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Primary Efficacy Endpoint</content>
                              </paragraph>
                              <paragraph>The primary efficacy endpoint was confirmed CMV DNA level &lt; LLOQ (i.e;, &lt;137 IU/mL) as assessed by COBASÂ® AmpliPrep/COBASÂ® TaqManÂ® CMV test) at the end of Week 8. The key secondary endpoint was CMV DNA level &lt; LLOQ and CMV infection symptom control at the end of Study Week 8 with maintenance of this treatment effect through Study Week 16.</paragraph>
                              <paragraph>For the primary endpoint, LIVTENCITY was statistically superior to IAT (56% vs 24%, respectively), as shown in Table 10.</paragraph>
                              <table width="80%">
                                 <caption>Table 10: Primary Efficacy Endpoint Analysis at Week 8 (Randomized Set) in Trial 303</caption>
                                 <col width="55%" align="left" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">LIVTENCITY<br/>400 mg<br/>Twice Daily<br/>N=235<br/> n (%)</th>
                                       <th styleCode="Rrule" valign="middle">IAT<br/>N=117<br/> n (%)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left">CI=confidence interval; CMV=cytomegalovirus; IAT=investigator-assigned anti-CMV treatment; N=number of patients.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Primary Endpoint: Confirmed CMV DNA Level &lt; LLOQ at Week 8<footnote>Confirmed CMV DNA level &lt; LLOQ at the end of Week 8 (2 consecutive samples separated by at least 5 days with DNA levels &lt; LLOQ [i.e:, &lt;137 IU/mL]).</footnote>
                                          </content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Responders</td>
                                       <td styleCode="Rrule">131 (56)</td>
                                       <td styleCode="Rrule">28 (24)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Adjusted difference in proportion of responders (95% CI)<footnote ID="foot7">Cochran-Mantel-Haenszel weighted average approach was used for the adjusted difference in proportion (maribavir â IAT), the corresponding 95% CI, and the p-value after adjusting for the transplant type and baseline plasma CMV DNA concentration. Only those with both stratification factors were included in the computation.</footnote>
                                       </td>
                                       <td styleCode="Rrule">33 (23, 43)</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">p-value: adjusted<footnoteRef IDREF="foot7"/>
                                       </td>
                                       <td styleCode="Rrule">&lt;0.001</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The reasons for failure to meet the primary endpoint are summarized in Table 11.</paragraph>
                              <table width="75%">
                                 <caption>Table 11: Analysis of Failures for Primary Efficacy Endpoint</caption>
                                 <col width="50%" align="left" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="top">Outcome at Week 8</th>
                                       <th styleCode="Rrule" valign="top">LIVTENCITY<br/> N=235<br/> n (%)</th>
                                       <th styleCode="Rrule" valign="top">IAT<br/> N=117<br/> n (%)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left">CMV=Cytomegalovirus, IAT=Investigator-assigned anti-CMV Treatment, MBV=maribavir.</td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left">Percentages are based on the number of subjects in the Randomized Set.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Responders (Confirmed DNA Level &lt; LLOQ)<footnote>Confirmed CMV DNA level &lt; LLOQ at the end of Week 8 (2 consecutive samples separated by at least 5 days with DNA levels &lt; LLOQ [i.e:, &lt;137 IU/mL]).</footnote>
                                          </content>
                                       </td>
                                       <td styleCode="Rrule" valign="top">
                                          <content styleCode="bold">131 (56)</content>
                                       </td>
                                       <td styleCode="Rrule" valign="top">
                                          <content styleCode="bold">28 (24)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Non-responders:</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">104 (44)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">89 (76)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â <content styleCode="bold">Due to virologic failure<footnote ID="foot8">CMV DNA breakthrough=achieved confirmed CMV DNA level &lt; LLOQ and subsequently became detectable.</footnote>:</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">80 (34)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">42 (36)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">														 														 																Â Â Â Â â¢Â Â CMV DNA never &lt; LLOQ</td>
                                       <td styleCode="Rrule">48 (20)</td>
                                       <td styleCode="Rrule">35 (30)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">													Â Â Â Â â¢Â Â CMV DNA breakthrough<footnoteRef IDREF="foot8"/>
                                       </td>
                                       <td styleCode="Rrule">32 (14)</td>
                                       <td styleCode="Rrule">7 (6)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â <content styleCode="bold">Due to drug/study discontinuation:</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">21 (9)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">44 (38)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">													Â Â Â Â â¢Â Â Adverse events</td>
                                       <td styleCode="Rrule">8 (3)</td>
                                       <td styleCode="Rrule">26 (22)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">															Â Â Â Â â¢Â Â Deaths</td>
                                       <td styleCode="Rrule">10 (4)</td>
                                       <td styleCode="Rrule">3 (3)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Â Â â¢Â Â Withdrawal of consent</td>
                                       <td styleCode="Rrule">1 (&lt;1)</td>
                                       <td styleCode="Rrule">9 (8)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">		Â Â Â Â â¢Â Â Other reasons<footnote>Other reasons=other reasons not including adverse events, deaths and lack of efficacy, withdrawal of consent, and non-compliance.</footnote>
                                       </td>
                                       <td styleCode="Rrule">2 (1)</td>
                                       <td styleCode="Rrule">6 (5)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â <content styleCode="bold">Due to other reasons but remained on study<footnote>Includes subjects who completed study assigned treatment and were non-responders.</footnote>
                                          </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">3 (1)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">3 (3)</content>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The treatment effect of LIVTENCITY was consistent across transplant type, age group, and the presence of CMV syndrome/disease at baseline. However, LIVTENCITY was less effective against subjects with increased CMV DNA levels (â¥50,000 IU/mL) and subjects with absence of genotypic resistance <content styleCode="italics">(see <linkHtml href="#Table12">Table 12</linkHtml>)</content>.</paragraph>
                              <table ID="Table12" width="90%">
                                 <caption>Table 12: Responders by Subgroup in Trial 303</caption>
                                 <col width="40%" align="left" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="2">LIVTENCITY 400 mg<br/>Twice Daily<br/>N=235</th>
                                       <th valign="bottom" styleCode="Rrule" colspan="2">IAT<br/>N=117</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">n/N</th>
                                       <th styleCode="Rrule">%</th>
                                       <th styleCode="Rrule">n/N</th>
                                       <th styleCode="Rrule">%</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Transplant type</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â SOT</td>
                                       <td styleCode="Rrule">79/142</td>
                                       <td styleCode="Rrule">56</td>
                                       <td styleCode="Rrule">18/69</td>
                                       <td styleCode="Rrule">26</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â HSCT</td>
                                       <td styleCode="Rrule">52/93</td>
                                       <td styleCode="Rrule">56</td>
                                       <td styleCode="Rrule">10/48</td>
                                       <td styleCode="Rrule">21</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Baseline CMV DNA viral load</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Low (&lt;9,100 IU/mL)</td>
                                       <td styleCode="Rrule">95/153</td>
                                       <td styleCode="Rrule">62</td>
                                       <td styleCode="Rrule">21/85</td>
                                       <td styleCode="Rrule">25</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Intermediate (â¥9,100 to &lt;91,000 IU/mL)</td>
                                       <td styleCode="Rrule">32/68</td>
                                       <td styleCode="Rrule">47</td>
                                       <td styleCode="Rrule">5/25</td>
                                       <td styleCode="Rrule">20</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Â Â â¥9,100 to &lt;50,000 IU/mL</td>
                                       <td styleCode="Rrule">29/59</td>
                                       <td styleCode="Rrule">49</td>
                                       <td styleCode="Rrule">4/20</td>
                                       <td styleCode="Rrule">20</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Â Â â¥50,000 to &lt;91,000 IU/mL</td>
                                       <td styleCode="Rrule">3/9</td>
                                       <td styleCode="Rrule">33</td>
                                       <td styleCode="Rrule">1/5</td>
                                       <td styleCode="Rrule">20</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â High (â¥91,000 IU/mL)</td>
                                       <td styleCode="Rrule">4/14</td>
                                       <td styleCode="Rrule">29</td>
                                       <td styleCode="Rrule">2/7</td>
                                       <td styleCode="Rrule">29</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Genotypic resistance to other anti-CMV agents</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Yes</td>
                                       <td styleCode="Rrule">76/121</td>
                                       <td styleCode="Rrule">63</td>
                                       <td styleCode="Rrule">14/69</td>
                                       <td styleCode="Rrule">20</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â No</td>
                                       <td styleCode="Rrule">42/96</td>
                                       <td styleCode="Rrule">44</td>
                                       <td styleCode="Rrule">11/34</td>
                                       <td styleCode="Rrule">32</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">CMV syndrome/disease at baseline</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Yes</td>
                                       <td styleCode="Rrule">10/21</td>
                                       <td styleCode="Rrule">48</td>
                                       <td styleCode="Rrule">1/8</td>
                                       <td styleCode="Rrule">13</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â No</td>
                                       <td styleCode="Rrule">121/214</td>
                                       <td styleCode="Rrule">57</td>
                                       <td styleCode="Rrule">27/109</td>
                                       <td styleCode="Rrule">25</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Age Group</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â 18 to 44 years</td>
                                       <td styleCode="Rrule">28/55</td>
                                       <td styleCode="Rrule">51</td>
                                       <td styleCode="Rrule">8/32</td>
                                       <td styleCode="Rrule">25</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â 45 to 64 years</td>
                                       <td styleCode="Rrule">71/126</td>
                                       <td styleCode="Rrule">56</td>
                                       <td styleCode="Rrule">19/69</td>
                                       <td styleCode="Rrule">28</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â â¥65 years</td>
                                       <td styleCode="Rrule">32/54</td>
                                       <td styleCode="Rrule">59</td>
                                       <td styleCode="Rrule">1/16</td>
                                       <td styleCode="Rrule">6</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240328"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="324079c5-be9d-4262-93f6-c2f854d51a22"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Secondary Endpoints</content>
                              </paragraph>
                              <paragraph>Table 13 shows results of the secondary endpoint, achievement of CMV DNA level &lt; LLOQ and symptom control<sup>a</sup> at Week 8 with maintenance through Week 16.</paragraph>
                              <table width="90%">
                                 <caption>Table 13: Achievement of CMV DNA Level &lt; LLOQ and CMV Infection Symptom Control at Week 8, With Maintenance Through Week 16<footnote>CMV infection symptom control was defined as resolution or improvement of tissue-invasive disease or CMV syndrome for symptomatic patients at baseline, or no new symptoms for patients who were asymptomatic at baseline.</footnote>
                                 </caption>
                                 <col width="60%" align="left" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">LIVTENCITY<br/> 400 mg<br/>Twice Daily<br/> N=235<br/> n (%)</th>
                                       <th valign="middle" styleCode="Rrule">IAT<br/>N=117<br/> n (%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Responders</td>
                                       <td styleCode="Rrule">44 (19)</td>
                                       <td styleCode="Rrule">12 (10)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Adjusted difference in proportion of responders (95% CI)<footnote ID="foot9">Cochran-Mantel-Haenszel weighted average approach was used for the adjusted difference in proportion (maribavir â IAT), the corresponding 95% CI, and the p-value after adjusting for the transplant type and baseline plasma CMV DNA concentration. Only those with both stratification factors were included in the computation.</footnote>
                                       </td>
                                       <td styleCode="Rrule">9 (2,17)</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">p-value: adjusted<footnoteRef IDREF="foot9"/>
                                       </td>
                                       <td styleCode="Rrule">0.013</td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240328"/>
                           <component>
                              <section>
                                 <id root="d5468850-05fb-4fbc-aba3-081d95958d13"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Virologic relapse during follow-up period: After the end of treatment phase, 65/131 (50%) of subjects in the LIVTENCITY group and 11/28 (39%) subjects in the IAT group who achieved CMV DNA level &lt; LLOQ experienced virologic relapse during the follow-up period. Most of the relapses 58/65 (89%) in LIVTENCITY group and 11/11 (100% in IAT group)] occurred within 4 weeks after study drug discontinuation; and the median time to relapse after CMV DNA level &lt; LLOQ was 15 days (range 7, 71) in the LIVTENCITY group and 15 days (range 7, 29) in the IAT group <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20240328"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="52c22579-1836-4444-b2f6-9fda6fa8e895"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>New onset symptomatic CMV infection: For the entire study period, a similar percentage of subjects in each treatment group developed new onset symptomatic CMV infection (LIVTENCITY 6% [14/235]; IAT 6% [7/113]).</paragraph>
                                 </text>
                                 <effectiveTime value="20240328"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="f55f3ab9-5b12-4d0c-a43a-645fff7615f7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Overall mortality: All-cause mortality was assessed for the entire study period. A similar percentage of subjects in each treatment group died during the trial (LIVTENCITY 11% [27/235]; IAT 11% [13/117]).</paragraph>
                                 </text>
                                 <effectiveTime value="20240328"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="0d525e14-c629-4846-ae47-54d415500e41"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Tablet: 200 mg, blue, oval shaped convex tablet debossed with "SHP" on one side and "620" on the other side. They are supplied as follows:</paragraph>
                  <paragraph>Bottles of 28 tablets with child-resistant caps (NDC 64764-800-28)</paragraph>
                  <paragraph>Bottles of 56 tablets with child-resistant caps (NDC 64764-800-56)</paragraph>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <section>
                     <id root="f52d6ddb-ee30-45e2-b92d-fc8395e8e2c9"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>Store at 20Â°C to 25Â°C (68Â°F to 77Â°F), brief exposure to 15Â°C to 30Â°C (59Â°F to 86Â°F) permitted <content styleCode="italics">[see USP Controlled Room Temperature]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20240328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="ed846bfa-f096-4288-967b-6eada8b39933"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</paragraph>
                  <paragraph>Inform patients that LIVTENCITY may interact with other drugs. Advise patients to report to their healthcare provider the use of any other medication <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml> and <linkHtml href="#S5.3">5.3)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. 						</paragraph>
               </text>
               <effectiveTime value="20240328"/>
            </section>
         </component>
         <component>
            <section>
               <id root="7abe0eb4-452a-41ea-a1e2-85071cb98eb7"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Takeda Pharmaceuticals America, Inc.</content>
                     <br/> Lexington, MA 02421</paragraph>
                  <paragraph>LIVTENCITY<sup>Â®</sup> and the LIVTENCITY Logo<sup>Â®</sup> are registered trademarks of Takeda Pharmaceuticals International AG.</paragraph>
                  <paragraph>TAKEDA<sup>Â®</sup> and the TAKEDA Logo<sup>Â®</sup> are registered trademarks of Takeda Pharmaceutical Company Limited.</paragraph>
                  <paragraph>Â©2024 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.</paragraph>
                  <paragraph>MAR358 R4</paragraph>
               </text>
               <effectiveTime value="20240328"/>
            </section>
         </component>
         <component>
            <section>
               <id root="52613a56-db92-47e0-92d5-c4c7ac66a716"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="2%" align="left" valign="top"/>
                     <col width="48%" align="left" valign="top"/>
                     <col width="30%" align="left" valign="top"/>
                     <col width="20%" align="right" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" colspan="4" align="center">Patient Information<br/> LIVTENCITY (liv-TEN-city)<br/> (maribavir)<br/> tablets</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td colspan="3" align="left">This Patient Information has been approved by the U.S. Food and Drug Administration.Â Â Â Â Â Â Â Â Â Â MAR358 R4</td>
                           <td align="right">Revised: March 2024</td>
                        </tr>
                        <tr>
                           <td align="left"/>
                           <td align="left"/>
                           <td align="left"/>
                           <td align="left"/>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">What is LIVTENCITY?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">LIVTENCITY is a prescription medicine used to treat cytomegalovirus (CMV) infection and disease in adults and children 12 years of age and older weighing at least 77 pounds (35 kg) who have received a transplant, when their infection or disease does not respond to treatment with the medicines ganciclovir, valganciclovir, cidofovir or foscarnet.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">It is not known if LIVTENCITY is safe and effective in children under 12 years of age.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">Before taking LIVTENCITY, tell your healthcare provider about all your medical conditions, including if you:</content>
                              <list styleCode="disc" listType="unordered">
                                 <item>are pregnant or plan to become pregnant. It is not known if LIVTENCITY will harm your unborn baby.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if LIVTENCITY passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with LIVTENCITY.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">Tell your healthcare provider about all of the medicines you take,</content> including prescription and over-the-counter medicines, vitamins and herbal supplements. LIVTENCITY may affect the way other medicines work, and other medicines may affect how LIVTENCITY works and cause serious side effects.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">Especially tell your healthcare provider if you take a seizure (anticonvulsant) medicine.<list styleCode="disc" listType="unordered">
                                 <item>You can ask your healthcare provider or pharmacist for a list of medicines that interact with LIVTENCITY.</item>
                                 <item>
                                    <content styleCode="bold">Do not start a new medicine without telling your healthcare provider</content>
                                    <content styleCode="bold">.</content> Your healthcare provider will tell you if it is safe to take LIVTENCITY with other medicines.</item>
                                 <item>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">How should I take LIVTENCITY?</content>
                              <list styleCode="disc" listType="unordered">
                                 <item>Take LIVTENCITY exactly as your healthcare provider tells you to take it.</item>
                                 <item>Take LIVTENCITY 2 times a day.</item>
                                 <item>Take LIVTENCITY with or without food.</item>
                                 <item>Swallow LIVTENCITY tablets whole. </item>
                                 <item>If you are not able to swallow tablets whole, you can break apart (disperse) the tablets in drinking water <content styleCode="bold">or</content> crush the tablets and mix with drinking water and take by mouth. <content styleCode="bold">See the "<linkHtml href="#IFU">Instructions for Use</linkHtml>" for detailed instructions</content> on how to prepare and give a dose of LIVTENCITY tablets by dispersing or crushing tablets and taking by mouth. </item>
                                 <item>If you have a Nasogastric (NG) or Orogastric (OG) Tube (French size 10 or larger), you can disperse the tablets and take through a NG or OG tube. <content styleCode="bold">See the "<linkHtml href="#IFU">Instructions for Use</linkHtml>" for detailed instructions</content> on how to prepare and give a dose of LIVTENCITY tablets through a NG or OG Tube. </item>
                                 <item>If you take too much LIVTENCITY, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">What are the possible side effects of LIVTENCITY?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">The most common side effects of LIVTENCITY include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list styleCode="disc" listType="unordered">
                                 <item>changes in taste</item>
                                 <item>nausea</item>
                                 <item>diarrhea</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list styleCode="disc" listType="unordered">
                                 <item>vomiting</item>
                                 <item>tiredness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">These are not all the possible side effects of LIVTENCITY.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">How should I store LIVTENCITY?</content>
                              <list styleCode="disc" listType="unordered">
                                 <item>Store LIVTENCITY at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">Keep LIVTENCITY and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">General information about the safe and effective use of LIVTENCITY.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="4">Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use LIVTENCITY for a condition for which it was not prescribed. Do not give LIVTENCITY to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about LIVTENCITY that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">What are the ingredients in LIVTENCITY?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">Active ingredient:</content> maribavir</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">Inactive ingredients:</content> FD&amp;C Blue #1, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium starch glycolate, titanium dioxide, and talc.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">Distributed by: <content styleCode="bold">Takeda Pharmaceuticals America, Inc.,</content> Lexington, MA 02421<br/>  LIVTENCITY<sup>Â®</sup> and the LIVTENCITY Logo<sup>Â®</sup> are registered trademarks of Takeda Pharmaceuticals International AG. TAKEDA<sup>Â®</sup> and the TAKEDA Logo<sup>Â®</sup> are registered trademarks of Takeda Pharmaceutical Company Limited. Â©2024 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.<br/> For more information, go to <linkHtml href="www.explorelivtencity.com">www.explorelivtencity.com</linkHtml> or call 1-877-TAKEDA-7 (1-877-825-3327).</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20240328"/>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="42332840-530f-437a-901c-f3d2dde9d26b"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions for Use</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">LIVTENCITY (liv-TEN-city)<br/>(maribavir)<br/>tablets, for oral use</content>
                  </paragraph>
                  <paragraph>This Instructions for Use contains information on how to prepare and give a dose of LIVTENCITY tablets by breaking apart (dispersing) or crushing in drinking water and taking by mouth; <content styleCode="bold">or</content> dispersing and giving through a Nasogastric (NG) or Orogastric (OG) Tube. Read this Instructions for Use before you prepare or give the first dose of LIVTENCITY, and each time you get a refill. Ask your healthcare provider or pharmacist if you have any questions.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before preparing a dose of LIVTENCITY:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>You can break apart (disperse) the tablets in drinking water <content styleCode="bold">or</content> crush the tablets and mix with drinking water. The tablet will not be completely dispersed in the mixture.</item>
                     <item>
                        <content styleCode="bold">Do not</content> mix LIVTENCITY with any liquid other than drinking water.</item>
                     <item>LIVTENCITY tablets that have been dispersed in drinking water can be given through a Nasogastric (NG) or Orogastric (OG) tube (French size 10 or larger).</item>
                     <item>You can prepare the mixture ahead of time and store at room temperature 68Â°F to 77Â°F (20Â°C to 25Â°C) for up to 8 hours.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Preparing a dose of LIVTENCITY by dispersing or crushing tablets and taking by mouth:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Gather the following supplies:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>small, clean container to place tablets and water in</item>
                     <item>drinking water</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step 1:</content> Choose a clean, flat work surface. Place all supplies on the work surface.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 2:</content> Wash and dry your hands well.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 3:</content> Get the prescribed number of LIVTENCITY tablets needed to prepare the dose.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 4:</content> Place the LIVTENCITY tablets into the container.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Note: If you prefer, you can crush the tablets with a spoon before adding water.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 5:</content> Add the amount of drinking water needed for your prescribed dose.</paragraph>
                  <table width="50%">
                     <col width="40%" align="center" valign="bottom"/>
                     <col width="60%" align="center" valign="bottom"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule">Number of Tablets</th>
                           <th styleCode="Rrule">Amount of Drinking Water</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">2</td>
                           <td styleCode="Rrule">30 mL</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">4</td>
                           <td styleCode="Rrule">60 mL</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">6</td>
                           <td styleCode="Rrule">90 mL</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Step 6:</content> Swirl the container gently to disperse the tablets in the water and swallow the mixture right away. The mixture will have a bitter taste.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 7:</content> Rinse the container with 15 mL of drinking water and swallow the mixture.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Repeat Step 7.</content> Check that no pieces of tablet are left in the container. Repeat <content styleCode="bold">Step 7</content> until no pieces remain.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Preparing and giving a dose of LIVTENCITY through a Nasogastric (NG) or Orogastric (OG) Tube:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Gather the following supplies:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>50 mL or 60 mL syringe</item>
                     <item>drinking water</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step 1:</content> Remove the cap (if capped) and plunger out of a 50 mL or 60 mL syringe. Add 2 tablets into the syringe body and place the plunger back in the syringe.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Note: Only 2 tablets can be given through the NG or OG tube at a time.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 2:</content> Withdraw 30 mL of drinking water into the syringe.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 3:</content> Hold the syringe with the tip pointing upward. Pull the plunger back so there is some air space in the syringe. If there is a cap, place the cap back on the syringe. Shake the syringe well for about 30 to 45 seconds or until the tablets are completely dispersed. Be careful not to spill the contents of the syringe.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 4:</content> Remove the cap (if capped) from the syringe again and attach the syringe to the NG or OG tube and give the mixture right away.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 5:</content> Withdraw 15 mL of drinking water into the same syringe and flush through the NG or OG tube.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Repeat Step 5.</content> Check that no pieces of tablet are left in the syringe. Repeat <content styleCode="bold">Step 5</content> until no pieces remain.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Note:</content> If your prescribed dose is more than 2 tablets, Repeat <content styleCode="bold">Steps 1 through 5</content> until you give the full prescribed dose.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storing LIVTENCITY:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Store LIVTENCITY at room temperature 68Â°F to 77Â°F (20Â°C to 25Â°C).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep LIVTENCITY and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For more information, go to <linkHtml href="www.explorelivtencity.com">www.explorelivtencity.com</linkHtml> or call 1-877-TAKEDA-7 (1-877-825-3327).</content>
                  </paragraph>
                  <paragraph>Distributed by: <content styleCode="bold">Takeda Pharmaceuticals America, Inc.,</content> Lexington, MA 02421</paragraph>
                  <paragraph>LIVTENCITY<sup>Â®</sup> and the LIVTENCITY Logo<sup>Â®</sup> are registered trademarks of Takeda Pharmaceuticals International AG. TAKEDA<sup>Â®</sup> and the TAKEDA Logo<sup>Â®</sup> are registered trademarks of Takeda Pharmaceutical Company Limited. Â©2024 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.<br/>MAR358 R4<br/>Revised: March 2024</paragraph>
               </text>
               <effectiveTime value="20240328"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2c9aed14-c422-4302-8e80-2da79f69ebc5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Bottle Carton</title>
               <text>
                  <paragraph>NDC 64764-800-28</paragraph>
                  <paragraph>LIVTENCITY<br/> (maribavir) tablets<br/> 200 mg</paragraph>
                  <paragraph>Rx Only<br/> 28 Tablets</paragraph>
                  <paragraph>For Oral Use</paragraph>
                  <paragraph>Takeda</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 200 mg Bottle Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="livtencity-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>